May 28, 2020 Oncopeptides reinitiates patient enrollment to the melflufen clinical program following a temporary pause due to the COVID-19 pandemic
May 22, 2020 Oncopeptides completes enrollment to the pivotal phase 3 study OCEAN for relapsed refractory multiple myeloma – 450 patients included
May 21, 2020 Carisma Therapeutics to Present and Meet with Potential Investors at Upcoming Healthcare Investor Conferences
May 20, 2020 Strongbridge Biopharma plc Announces $30 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.